15th edition of CTAD – from November 29 to December 2, 2022 REGEnLIFE presents the Light4life study project, a pivotal clinical study to assess the therapeutic efficacy of its photomedical technology in Alzheimer’s disease.
As part of the 15th edition of the CTAD (Clinical Trials on Alzheimer’s Disease) which takes place from November 29 to December 2, 2022 in San Francisco (United States), REGEnLIFE, a French company specializing in the research and development of innovative technologies in photo-medicine for the prevention and treatment of neurodegenerative diseases, will present the concept of its next clinical study, Light4life.
This pivotal study, which will be conducted in France in 2023 with 108 patients suffering from Alzheimer’s disease, aims to assess the cognitive impacts of a PhotoBioModulation (PBM) treatment, an innovative non-invasive therapy acting on the inflammation of the brain-gut axis, which would be responsible for the development of Alzheimer’s disease and other neurodegenerative diseases. In 2020, more than 55 million people suffered from dementia worldwide¹ and more than 1.2 million among the over 65s in France². Currently, there is no treatment to cure this disease.
An innovative, non-invasive and promising technology in the treatment of Alzheimer’s disease REGEnLIFE’s photobiomodulation medical device, called RGn600, uses infrared photon emissions, and will target both the brain and the intestine patients with a helmet and a lap belt. A pilot clinical trial conducted from 2018 to 2020 in around 50 patients aged 55 to 85 with mild to moderate Alzheimer’s disease demonstrated the safety, ease of use of the treatment and improvement in certain cognitive functions of patients in just 2 months of intervention³.
For Dr. Patrice Cristofini, CEO of REGEnLIFE, the company’s participation in the CTAD – a gathering of leaders in Alzheimer’s disease research from the industrial and academic worlds – the publication of the pilot study in a scientific journal of reference on Alzheimer’s disease and the ongoing constitution of a prestigious scientific council “will allow REGEnLIFE to take its full place in the world market for Alzheimer’s disease treatments thanks to its innovative therapeutic approaches. It also makes a French contribution to this global public health issue.”
REGEnLIFE is a company specializing in the research and development of innovative technologies in photo-medicine for the prevention and treatment of neurodegenerative diseases. The company aims to offer a photo-medical technology targeting both the brain and the intestine, in particular for the treatment of Alzheimer’s disease. Innovative technology and notREGEnLIFE’s invasive technique, which is undergoing clinical evaluation, is based in particular on the emission of combined infrared waves at the level of the skull and abdomen, using an electronically controlled helmet and abdominal belt.
REGEnLIFE brings together a multidisciplinary team and partners including experts and researchers in many fields: engineering, optics, photonics, electronics, new technologies, physical sciences, public health, medicine, neurology and neurosciences. It benefits from the support of private investors, as well as Bpifrance and the Occitanie Region on several of its R&D projects. REGEnLIFE is currently finalizing a new fundraiser. Based in Paris and Occitanie, REGEnLIFE brings together a team of eight people. https://regenlife.com/